Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

Fluocinolone implants can slow diabetic retinopathy and delay proliferation in patients with diabetic macular edema, researchers say. Compared with antivascular endothelial growth factor (anti-VEGF) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes did not have higher risk for ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...

A recent study published in the journal Nature Medicine showed that targeting senescent cells in the retina can be a lasting disease-modifying treatment for diabetic macular edema (DME). The retina is ...

Please provide your email address to receive an email when new articles are posted on . The approval was supported by 1-year results from the phase 3 Pagoda study. Susvimo is also approved for wet age ...

Joseph M. Coney, MD, FACS, reviews best practices for improving adherence to treatment among patients with diabetic macular edema through comprehensive education on the disease and available therapies ...

Intraretinal hyperreflective foci, intraretinal hard exudates, and epiretinal membrane formation were lower after treatment with faricimab (Vabysmo) compared with aflibercept (Eylea) for patients with ...